NATALIZUMAB - Keresési eredmények

Európai Unió - magyar - EMA (European Medicines Agency)

natalizumab elan pharma

elan pharma international ltd. - natalizumabot - crohn-betegség - immunostimulants, - kezelés a közepesen súlyos, aktív crohn-betegség csökkentésére tünetek, valamint az indukciós, karbantartás tartós válasz, illetve elengedése, azoknál a betegeknél, akik nem reagáltak annak ellenére, hogy teljes körű, megfelelő terápia egy kortikoszteroid egy immunszuppresszív; vagy intoleráns vagy orvosi ellenjavallat, hogy az ilyen terápiák.

Európai Unió - magyar - EMA (European Medicines Agency)

tyruko

sandoz gmbh - natalizumabot - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunszuppresszánsok - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 és 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.

Európai Unió - magyar - EMA (European Medicines Agency)

tysabri

biogen netherlands b.v. - natalizumabot - szklerózis multiplex - szelektív immunszuppresszánsok - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 és 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Európai Unió - magyar - EMA (European Medicines Agency)

dimethyl fumarate neuraxpharm

laboratorios lesvi s.l. - dimetil-fumarát - a sclerosis multiplex, a relapszáló-remittáló - immunszuppresszánsok - dimethyl fumarate neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.